

CEFTAZIDIME with AVIBACTAM

BRAND NAME ZAVICEFTA
DRUG CLASS Cephalosporin antibiotic with beta lactamase inhibitor
AVAILABILITY Vial contains 2000 mg of ceftazidime and 500 mg of avibactam as avibactam sodium. Also contains sodium carbonate. Contains 6.4 mmol of sodium.¹

WARNING Contraindicated in patients with severe immediate (IgE mediated) or severe delayed (T-cell mediated) hypersensitivity to penicillins. Seek specialist advice for patients with non-severe immediate hypersensitivity to penicillins.

pH No information

PREPARATION Reconstitute the vial with 10 mL of water for injections. Shake gently to dissolve. Insert an airway needle to relieve pressure and avoid product loss. The solution is clear and colourless to yellow.¹ It may take up to 4 minutes to dissolve.¹
The concentration is 167.3 mg/mL of ceftazidime and 42 mg/mL of avibactam.¹
Powder volume – 1.95 mL¹

Dose	Volume of reconstituted solution
2000 mg/500 mg	12 mL
1000 mg/250 mg	6 mL
750 mg/187.5 mg	4.5 mL

STABILITY Vial: store below 30 °C. Protect from light.¹
Reconstituted solution: use immediately.¹
Infusion solution: stable in an infusion bag for 12 hours below 25 °C or 24 hours at 2 to 8 °C. Stable in a syringe for 6 hours below 25 °C.¹

ADMINISTRATION
IM injection Not recommended
SUBCUT injection Not recommended
IV injection Not recommended
IV infusion Dilute the dose in 100 mL of a compatible fluid and infuse over 2 hours.¹
A volume of 50 mL can be used if necessary. The 2000 mg/500 mg dose can be diluted in 250 mL of compatible fluid if preferred.¹
The infusion is given over 2 hours regardless of volume.
IV use in infants and children Dilute the dose to 8–40 mg/mL of ceftazidime. Infuse over 2 hours.¹

COMPATIBILITY
Fluids Glucose 5%¹, Hartmann's¹, sodium chloride 0.9%¹, sodium chloride 0.45% and glucose 2.5%¹
Y-site For **2 hours**: aztreonam (in sodium chloride 0.9%)²
Some visual compatibility information is available.³

INCOMPATIBILITY
Fluids No information
Drugs Aminoglycosides: amikacin, gentamicin, tobramycin⁴

SPECIAL NOTES Monitor the infusion site, may cause phlebitis.¹

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 18/03/2022.
2. O'Donnell JN, Xu A, Lodise TP. Intravenous compatibility of ceftazidime-avibactam and aztreonam using simulated and actual Y-site administration. *Clin Ther* 2020; 42: 1580-6.
3. Ceftazidime-avibactam In: IV Index [internet]. Trissel's 2 clinical pharmaceuticals database (parenteral compatibility). Greenwood Village, CO: IBM Watson Health. Accessed 18/03/2022.
4. McEvoy GK editor. Handbook on injectable drugs. 20th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2018.